Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thorough ECG (QT) study of EVK-001 (metoclopramide nasal spray) in healthy volunteers.

Trial Profile

Thorough ECG (QT) study of EVK-001 (metoclopramide nasal spray) in healthy volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metoclopramide (Primary)
  • Indications Diabetic gastroparesis
  • Focus Adverse reactions; Registrational
  • Sponsors Evoke Pharma
  • Most Recent Events

    • 24 May 2016 According to Evoke Pharma media release, this study was designed in accordance with published FDA and ICH guidance on the clinical evaluation of QT/QTc interval prolongation and the proarrhythmic potential of non-cardiac drugs.
    • 24 May 2016 Data from this study were presented at Digestive Disease Week (DDW) 2016, as per Evoke Pharma media release.
    • 17 Feb 2016 According to an Evoke Pharma media release, results from this study will be presented at the Digestive Disease Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top